Introduction
Interleukin-12 (IL-12) is a heterodimeric cytokine composed of 35 kDa (p35) and 40 kDa (p40) subunits [1] [2] [3] originally identified as a natural killer cell-stimulating factor [1] or as a cytotoxic lymphocyte maturation factor [2] . It has recently been demonstrated in preclinical studies that local or systemic treatment with IL-12 mediates profound antitumor effects, causing regression of established tumors and tumor metastases [4, 5] . Unfortunately, application of IL-12 in tumor therapy may be limited by its induction of toxic effects, including suppression of hematopoiesis [6] [7] [8] .
Numerous studies have shown an amino acid sequence homology betweenp35 and IL-6 and G-CSF [9] and between p40 and extracellular domains of the IL-6 and G-CSF receptors [10] . It has been demonstrated in many studies that IL-12 stimulates hematopoiesis in vitro [11, 12] . Nevertheless, IL-12-treated mice developed neutropenia [6, 7] resulting probably from enhanced IFN-y production [10] . Furthermore, a phase I dose-escalation trial of intravenous IL-12 in humans revealed severe neutropenia and lymphopenia [8] . In our study, we decided to examine whether application of G-CSF could prevent the development of some of the hematologic toxicities induced by IL-12 treatment. In accordance with our expectations, application of G-CSF prevented inhibition (suppression) of bone marrow myelopoiesis in IL-12-treated mice. However, in the MmB16 melanoma model, G-CSF also unexpectedly showed potentiation of the antitumor effects of IL-12.
Materials and methods
Mice (C57BL/6 x DBA/2)F, mice, hereafter called B6D2F,, 8-13 weeks of age and weighing 20-24 g, were used. Breeding pairs were obtained from the Inbred Mice Breeding Center of the Institute of Immunology and Experimental Medicine (Wroclaw, Poland). Mice were bred in a local animal facility and kept in conventional conditions with unlimited access to food and water during experiments. All experiments with animals were performed in accordance with the guidelines approved by the Ethical Committee of the Medical School of Warsaw.
Reagents
Recombinant human G-CSF (Neupogen) was purchased from Hoffman-La Roche, (Basel, Switzerland). Recombinant murine IL-12 (bioactivity 4.6 x 10 6 U/mg) was kindly provided by the Genetics Institute, Inc. (Boston, MA). The cytokines were diluted with 0.1% BSA (Sigma, St. Louis, MO) in PBS for in vivo experiments. Heparin (Sigma) was diluted in 0.9% NaCl.
Tumor
MmB16 melanoma (metastatic subclone of B16 melanoma, kindly provided by Prof. C. Radzikowski from the Institute of Immunology and Experimental Medicine, Wroclaw, Poland) was used in all of the experiments. Cells were cultured in RPMI-1640 medium (Gibco BRL, Paisley, UK) supplemented with 10% heat-inactivated fetal calf serum (FCS), antibiotics, 2-mercaptoethanol (50 urn) and L-glutamine (2 mm) (all from GIBCO BRL), hereafter called culture medium. Cells were maintained in 75 cm 2 tissue flasks (Corning, NY) at 37 °C in a humidified atmosphere of 5% CO 2 and passaged every 3-4 days after a short trypsinization with trypsin/EDTA (Gibco BRL). For in vivo experiments exponentially growing tumor cells were harvested from culture flasks and washed twice in cold RPMI-1640 medium. Cells were then resuspended in RPMI-1640 medium to a concentration of 5 x 10 7 cells/ml and injected (10 6 melanoma cells in 20 ul medium) into the footpad of the right hind limb of B6D2F! mice. Tumor cell viability ranged between 93% and 96%.
Cytokine administration
In the experiments in which the influence of IL-12 and/or G-CSF on hematopoiesis was studied in vivo, groups composed of six mice were treated intraperitoneally (i.p.) with either agent alone or the two in combination for seven consecutive days. IL-12 was given at a dose of 0.1 ug per injection adjusted to the volume of 50 ul 0.1% BSA-PBS. G-CSF was given twice daily at a dose of 1 ug also adjusted to the volume of 50 ul 0.1% BSA-PBS. Mice in control groups received 50 ul 0.1% BSA-PBS. In the experiments in which the influence of IL-12 and/or G-CSF on the number of white blood cells (WBC) in peripheral blood was studied in vivo, there were 6-7 melanoma-bearing mice in each group. They were treated intraperitoneally (i.p.) with either agent alone or in combination for seven consecutive days as described above.
Analysis of white blood cells
In order to collect peripheral blood for WBC analysis mice were anesthetized with ether and exsanguinated from the retroorbital sinus, four hours after injection of the last dose of cytokine(s). The blood was collected into tubes containing 500 ul of saline and 50 U heparin. After 2-3 hours WBC were assessed using Sysmex-820 cell counter (Sysmex, Kyoto, Japan) adjusted to the analysis of rodent cells.
Collection of bone marrow and spleen cells
To collect spleen and bone marrow cells mice were killed by cervical dislocation, and spleens and femora were removed. Spleens were homogenized in a glass homogenizer and the obtained cells were suspended in the Iscove's modified Dulbecco's medium (IMDM, Gibco) with the addition of 10% FCS. The femora were flushed out with IMDM using a syringe and a 21-gauge needle and cell suspension was diluted to the required concentration with IMDM and FCS. The cellularities of bone marrow and spleen were evaluated using Biirker's hemocytometer.
In vitro colony assays
For the GM-CFC assay, bone marrow (5 x 10 4 ) and spleen (5 x 10 5 ) cells were suspended in a semisolid medium composed of IMDM supplemented with 20% FCS, and 20% of WEHI cell line-conditioned medium (as a source of growth factors) and 0.8% methylcellulose (Daiichi, Japan). The cell suspensions were poured onto 35-mm Petri dishes (Falcon), and incubated for seven days at 37 °C, 5% CO 2 in a fully humidified atmosphere. Following the incubation the colonies were counted using an inverted microscope.
Tumor treatment and monitoring
In the experiments in which the antitumor effects of IL-12 and/or G-CSF were studied in vivo, melanoma-bearing mice were treated intratumorally (i.t.) with either agent alone or the two in combination for seven consecutive days, starting from day 7 following inoculation of 10 6 melanoma cells. IL-12 was given at a dose of 0.1 ug per injection adjusted to the volume of 20 ul 0.1% BSA-PBS. G-CSF was given twice daily at a dose of 1 ug, also adjusted to the volume of 20 ul 0.1% BSA-PBS. Mice in control groups received 20 ul 0.1% BSA-PBS intratumorally in the same regimen as treated mice. The doses of cytokines were chosen according to our earlier experiments [13, Golab et al. manuscript submitted] . Local tumor growth was determined by measuring footpad diameter in two dimensions (anterior-posterior and side-to-side) with calipers every two days, starting on the first day of treatment (day seven after inoculation of tumor cells -initial tumor volume).
Tumor volume was estimated by the formula:
Relative tumor volume was calculated as follows:
Relative tumor volume = ((tumor volume) -(initial tumor volume)) x 100%
Mice were observed daily for survival.
Ex vivo assay for macrophage nitric oxide (NO) synthesis
Peritoneal exudate cells were obtained by peritoneal lavage from B6D2Fi mice four hours after the last dose of i.p. IL-12 and/or G-CSF treatment (IL-12 at a dose of 0.1 ug was administered once daily and G-CSF at a dose of 1 ug was administered twice daily for seven consecutive days). Mice in control groups received 50 ul of 0.1% BSA-PBS. Lavages were performed with chilled PBS containing 10 U/ml heparin. Cells were washed twice in PBS, counted and resuspended in culture medium at a concentration of 5 x 10 6 cells/ml. After a two-hour incubation at 37 °C (5% CO 2 environment) in 92 x 21 mm plastic Petri dishes (Nunc) in culture medium, nonadherent cells were removed by gentle washing (three times) with warm RPMI-1640 medium. The adherent cells with morphological characteristics of macrophages were scraped with a rubber policeman, resuspended in warm culture medium at a concentration of 5 x 10 5 cells/ml and dispensed in a 96-well flat-bottomed microtiter plate at a concentration of 5 x 10 4 cells in 100 ul culture medium per well. Macrophages constituted approximately 85% of these cells (as determined by cytophotometric analysis of the isolated cells stained with a rat anti mouse F4/80 antigen monoclonal antibody (Serotec, Oxford, England)). After the two-hour incubation period (37 "C, 5% CO 2 in humidified atmosphere) 100 ul of culture medium or 5 x 10 3 MmB16 cells in 100 ul of culture medium were added to the wells. The cultures were incubated for 24 hours and then a stable metabolite of NO was quantified in culture supernatants using a colorimetric microtiter assay with Griess reagent. Briefly, samples of 100 ul were incubated with equal parts of 50 ul 1% sulphanilamide dihydrochloride (Sigma) in 5% H3PO4 and 0.1% N-(l-naphthyl)ethylendiamine (Sigma) in distilled water at room temperature for 15 min. The absorbency was determined with an enzyme-linked immunosorbent assay (ELISA) reader (SLTLabinstrument Ges.m.b.h., Salzburg, Austria) using a 540-nm filter. Concentrations were determined from a linear standard curve generated from 1.25 to 100 um sodium nitrite in culture medium. The means and standard deviations were determined for quadruplicate samples.
Assay for ex vivo cytotoxic activity of macrophages B6D2Fi mice were treated i.p. with IL-12 and/or G-CSF on the same dose schedules as described above. Four hours after the last injection peritoneal exudate cells were collected and macrophages isolated as described above. Cytotoxic activity of macrophages on melanoma cells was tested in a standard 18-hour 51 Cr-release assay. Target cells (10 6 /ml) were incubated with 100 uCi sodium chromate 51 (Amersham, Aylesbury, UK) in culture medium for one hour at 37 °C. Labeled cells were placed in a 96-well round-bottomed microtiter plate (Nunc) at 10 s cells/well in 100 ul culture medium. Subsequently effector cells in 100 ul culture medium were added to the targets at effector to target ratios: 40:1, 20:1, or 10: 1. After 18 hours of incubation at 37 °C, 5% CO 2 , 100 ul supernatants were collected and counted in a gamma counter. Maximal release was obtained by incubation of targets with detergent Triton 2% and spontaneous release was measured by counting supernatants of targets incubated with medium alone. The spontaneous release in each experiment was less than 30%. The percentage of specific lysis was calculated using the following formula: % specific lysis = ((experimental release -spontaneous release) -(maximal release -spontaneous release)) x 100
Determinations were done in triplicate. All ex vivo experiments were repeated at least three times. Results of representative experiments are presented.
Statistical analysis
Data are presented as a mean ± standard deviation (SD). Differences in data were analyzed for significance by Student's /-test (two-tailed).
(None of the animals were excluded from the statistical analysis.)
Results Bone marrow and spleen cells were isolated and their colony forming capabilities were evaluated as described in 'Materials and methods'. Results represent the mean ± SD. Student's Mest: "P < 0.01 -a statistically significant suppression of GM-CFC in the bone marrow following IL-12 treatment as compared with controls. Changes in peripheral blood WBC counts in IL-12 and/or G-CSF treated mice. Six to seven melanoma-bearing mice were used per group. Mice were treated with IL-12 (0.1 ug/injection) and/or G-CSF (1 mg/injection given twice daily) or with 0.1% BSA-PBS for seven consecutive days. Blood was collected on day 7, four hours after the last injection and analyzed using Sysmex-820 cell counter (Sysmex, Kyoto, Japan). Results represent the mean ± SD. a P < 0.01 versus controls, V < 0.01 versus IL-12-treated mice.
Influence of IL-12 and/or G-CSF on spleen and bone marrow GM-CFC
The administration of IL-12 at a dose of 0.1 ug once daily led to a decrease in the numbers of GM-CFC in the femoral bone marrow. Simultaneous administration of G-CSF at a dose of 1 ug twice daily together with IL-12 at a dose of 0.1 ug corrected this myelosuppressive effect of IL-12 ( Table 1 ). The spleen GM-CFC number increased after IL-12 administration as compared with controls. Administration of G-CSF together with IL-12 further increased the number of spleen GM-CFC, although this effect did not reach statistical significance (Table 1) .
Influence of IL-12 and/or G-CSF on the number of white blood cells in peripheral blood
IL-12 given at the low dose of 0.1 ug did not decrease peripheral blood granulocyte counts below those of controls. The observed changes in peripheral blood cells following this seven-day treatment are summarized in Table 2 . Administration of IL-12 resulted in a greater than two-fold decrease in total WBC, and in an almost three-fold decrease in lymphocyte counts. Unexpectedly, the addition of G-CSF to the IL-12 treatment led to complete restoration of the lymphocyte count ( Table 2) .
Influence of IL-12 and/or G-CSF on bone marrow and spleen cellularity
The administration of IL-12 led to enlargement of the spleens of all of the animals. The addition of G-CSF further increased the spleen masses in the treated mice. This effect correlated with spleen cellularities after the administration of both cytokines ( Table 3 ). The bone marrow cellularity did not change significantly after IL-12 and/or G-CSF administration.
Effects of IL-12 and/or G-CSF on the growth ofMmB16 melanoma in mice
In the in vivo experiment we examined the effect of IL-12 and G-CSF, used either alone or in combination, on MmB16 melanoma growth. Tumor treatment was started seven days after inoculation of 1 x 10 6 melanoma cells and was continued for seven consecutive days. As shown in Figure 1 , a seven-day treatment with G-CSF, at a dose of 1 ug per injection given twice daily, did not significantly influence tumor growth. However, repeated administration of IL-12 at a dose of 0.1 ug per injection elicited a statistically significant retardation of tumor growth as compared with controls (P < 0.05 on days 17-29) (Figure 1 ). We did not continue tumor measurement beyond day 29, as control mice began dying, and they as well as those in the G-CSF-treated group developed substantial tumor necrosis.
Treatment of tumor-bearing mice with G-CSF COm- bined with IL-12 resulted in further retardation of tumor growth as compared with that seen in mice treated with IL-12 alone. Significant retardation of tumor growth was observed on days: 11-21 (P < 0.05 on days 11, 19, 21, and P < 0.01 on days 13, 15, 17) as compared with IL-12-treated mice. The experiment was repeated twice and the results were comparable.
Analysis of mouse survival showed no statistically significant prolongation of survival time in mice treated with IL-12 combined with G-CSF over that of mice treated with IL-12 alone (the mean survival time was 54.7 ± 16.8 days and 55.8 ± 13.5 days for IL-12 and IL-12 + G-CSF treated mice, respectively). The mean survival time was, however, significantly prolonged by both treatment regiments as compared with controls (41.4 ± 9.7 days; P < 0.05). G-CSF did not significantly prolong the mean survival time of mice (47.7 ± 12.0 days).
Macrophage nitric oxide production and cytotoxicity
IL-12 acting on T and NK cells stimulates the secretion of IFN-y -a cytokine that activates macrophages and increases their tumoricidal activity, at least partly through secretion of nitric oxide (NO). G-CSF has also been shown to be an indirect activator of macrophages. Therefore we decided to determine the effect of IL-12 and G-CSF on these cells. Groups of mice were treated i.p. for seven consecutive days with IL-12 and/or G-CSF at the same cytokine doses as above. Intraperitoneal administration of IL-12 stimulated macrophages to produce substantial amounts of NO. The addition of G-CSF further augmented the secretion of NO, and this effect was statistically significant in contrast to the one in the IL-12-treated group (Figure 2) .
Next, we decided to assess whether the interaction between IL-12 and G-CSF is also evident as far as direct 1 
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Control G-CSF IL-12 IL-12* G-CSF Treatment groups Figure 2 Nitric oxide production by the peritoneal macrophages isolated from mice treated i.p. with either IL-12 (at a dose of 0.1 ug) and/or G-CSF (given twice daily at a dose of 1 ug per injection for seven days) or 0.1% BSA-PBS. Macrophages were incubated for 24 hours either alone or with MmB16 cells. Shown are the mean values of nitrite levels in supernatants ± SD, done in quadruplicate. *P < 0.05 as compared with all other groups (Student's f-test).
cytotoxic activity of macrophages is concerned. To this end we administered IL-12 and/or G-CSF i.p. at the same doses as in earlier experiments. The cytotoxic activity of peritoneal macrophages was evaluated in a standard 18-hour cytotoxic assay as described in Materials and methods (Figure 3a) . Although IL-12 did not significantly stimulate the cytotoxic activity of macrophages as compared with controls, the addition of G-CSF did exert a very strong stimulatory effect. This effect was evident in two effector-to-target ratios examined (40:1, 20 :1; P < 0.05 as compared with all other groups). Next, we decided to determine whether the effect of IL-12 and G-CSF was also evident at a lower effector-to-target ratio, namely at 10:1. At this ratio IL-12 preserved its insignificant stimulatory activity on macrophage cytotoxicity, and the addition of G-CSF further enhanced this effect (P < 0.05) (Figure 3b ). 
Conclusions
IL-12 has already been successfully used in many murine tumor models, having been found to both inhibit tumor growth and/or reduce the number of tumor metastases [4, 5] . We used intratumoral injections of IL-12 in our present study, because, in accord with earlier observations in the Renca tumor model [4] , intratumoral injection of IL-12 was more effective in our melanoma model than intraperitoneal IL-12 administration [Zagozdzon et al. manuscript in preparation].
Although IL-12 synergizes with other cytokines such as IL-3, IL-11, and Steel Factor in stimulating hematopoiesis in vitro [11, 12] , its administration in both mice and humans results in suppression of bone marrow and enhancement of spleen hematopoiesis [6] , leading to the development of neutropenia [6] [7] [8] . The inhibitory effects of IL-12 on in vivo hematopoiesis seem to result from IL-12-induced production of IFN-Y [7] . However, inactivation of IFN-y or blocking of its release and/or action should not be used as to prevent hematologic toxicity during IL-12 treatment, as IFN-y seems to participate strongly in the antitumor activity of IL-12 [14, 15] . Fortunately, effective measures to prevent hematologic toxicities have already been developed for the purposes of tumor chemotherapy. One of the approaches for diminishing detrimental effects of chemotherapy on hematopoiesis during tumor chemotherapy is the application of G-CSF. Administration of G-CSF after cytotoxic chemotherapy has been found to reduce the duration of neutropenia, the incidence of fever, the requirement for antibiotics, and the incidence of hospitalization [16] . Therefore, we decided to apply G-CSF to our IL-12-treated mice in order to diminish some of the hematologic toxicities developing as a result of IL-12 administration. We found that application of G-CSF prevented myelosuppressive effects of IL-12 with respect to the development of bone marrow granulocyte-macrophage colony forming cells (Table 1 ). The decrease in the total spleen number of GM-CFC in mice treated with both G-CSF and IL-12 as compared with mice treated with G-CSF alone is most probably due to the antiproliferative activity of IL-12-induced IFN-y [7] .
Although IL-12 administered at a dose of 0.1 ug did not produce a significant drop in granulocyte count, it caused a lymphopenia (an almost three-fold decrease in lymphocyte count). The addition of G-CSF to IL-12 treatment resulted in an increased granulocyte count (statistically non-significant) and unexpectedly completely reversed IL-12-induced lymphopenia ( Table 2 ). The ability of G-CSF to prevent hematopoietic suppression induced by higher IL-12 doses (causing granulocytopenia) needs to be explored in further studies.
As G-CSF could stimulate tumor growth under certain conditions in mice [17] , we decided to examine the influence of G-CSF application on the growth of MmB16 melanoma. G-CSF did not influence tumor growth when given alone but surprisingly it potentiated the antitumor activity of IL-12 ( Figure 1 ). Neither cytokine (used either alone or in combination in a vast range of doses) influenced the proliferative capacity of melanoma cells in vitro (as determined in a standard MTT assay; data not shown).
G-CSF has already been demonstrated to show antitumor effects when released locally from tumor cells engineered to express this cytokine [18, 19] . Tumor infiltration by neutrophils, macrophages, and T cells, and the cooperation of these cells and cytokines released by them, were all implicated in antitumor effects observed in the above-cited model [19] . We decided to examine whether macrophages could participate in potentiated antitumor effects of combined IL-12/G-CSF immunotherapy. The results of our study seem to support this possibility. The NO production by, and cytotoxic activity of, macrophages from mice treated with the combination of IL-12 and G-CSF were significantly higher than those of macrophages from mice treated with IL-12 alone (Figures 2 and 3) . Since the antitumor activity of IL-12 is mediated at least partly through IFN-y produced by IL-12-activated NK and T cells [14, 15] our observations are compatible with the results of previous studies demonstrating that IFN-y was able to stimulate monocytes' cytotoxicity towards tumor cells to significantly higher levels when these monocytes were isolated from G-CSF-treated patients [20] .
Neutrophils could also participate in antitumor effects observed in mice treated with a combination of IL-12 and G-CSF. Activation of neutrophil effector functions by IFN-y [21, 22] as well as by G-CSF [23, 24] has already been observed and augmented cytotoxicity of neutrophils towards Aspergillus fumigatus hyphae has also been demonstrated with the combination with these two cytokines [25] .
G-CSF has already been successfully used in chemotherapy dose-intensification studies [26] . It cannot be excluded that analogously to the above-mentioned doseintensification studies, G-CSF could be used to prevent or diminish some of the bone marrow toxicities of IL-12 in tumor-bearing patients, allowing administration of higher IL-12 doses. As IL-12 has already demonstrated potentiated antitumor activity when combined with some chemotherapeutics [Zagozdzon et al. manuscript in preparation] it may be assumed that IL-12 together with G-CSF could be successfully included in some of the combined chemo-immunotherapy schedules.
